A new treatment option for laryngeal sensory neuropathy

2009 ◽  
Vol 119 (9) ◽  
pp. 1844-1847 ◽  
Author(s):  
Stacey L. Halum ◽  
David L. Sycamore ◽  
Bryan R. McRae
Keyword(s):  
Treatment Option ◽  
Sensory Neuropathy ◽  
New Treatment

scholarly journals Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma

2015 ◽  
Vol 49 (4) ◽  
pp. 315-319 ◽  
Author(s):  
Barbara Jezersek Novakovic
Keyword(s):  
Overall Survival ◽  
Hodgkin Lymphoma ◽  
Treatment Option ◽  
Sensory Neuropathy ◽  
High Dose ◽  
Primary Therapy ◽  
Refractory Disease ◽  
Peripheral Sensory Neuropathy ◽  
New Treatment ◽  
Peripheral Sensory

Abstract Background. Even though Hodgkin lymphoma is a highly curable disease, some of the patients have either a refractory disease or experience a relapse following a successful primary therapy. Durable responses and remissions in patients with relapsed or refractory disease may be achieved in approximately one-half with salvage chemotherapy followed by high dose chemotherapy (HDT) and autologous hematopoietic cell rescue (SCT). On the other hand, patients who relapse after HDT and autologous SCT or those who have failed at least two prior multi-agent chemotherapy regimens and are not candidates for HDT have limited treatment options. Conclusions. A new treatment option in this population is an immunotoxin Brentuximab vedotin composed of a CD30 directed antibody linked to the antitubulin agent monomethyl auristatin E. It has demonstrated a substantial effectiveness and an acceptable toxicity. In the pivotal study, the overall response rate was 75% with 34% of complete remissions. The median durations of response were 20.5 and 6.7 months for those with complete remission and all responding patients, respectively. The median overall survival was 40.5 months (3-years overall survival 54%) and the median progression-free survival 9.3 months. The most common non-hematologic toxicities were peripheral sensory neuropathy, nausea, and fatigue while the most common severe side effects were neutropenia, thrombocytopenia, anemia, and peripheral sensory neuropathy.

Apremilast as a new treatment option for Acrodermatitis continua of Hallopeau

2019 ◽  
Vol 60 (3) ◽  
Author(s):  
Alba Calleja Algarra ◽  
Raquel Aragón Miguel ◽  
Virginia Velasco Tamariz ◽  
Marta Prieto Barrios ◽  
Juan José Andrés Lencina ◽  
...  
Keyword(s):  
Treatment Option ◽  
New Treatment

Daytime pulsed dose rate brachytherapy as a new treatment option for previously irradiated patients with recurrent oesophageal cancer

2005 ◽  
Vol 78 (927) ◽  
pp. 236-241 ◽  
Author(s):  
W Harms ◽  
R Krempien ◽  
C Grehn ◽  
C Berns ◽  
F W Hensley ◽  
...  
Keyword(s):  
Dose Rate ◽  
Treatment Option ◽  
Oesophageal Cancer ◽  
New Treatment ◽  
Pulsed Dose Rate

scholarly journals Inactivation of Cytomegalovirus in Breast Milk Using Ultraviolet-C Irradiation: Opportunities for a New Treatment Option in Breast Milk Banking

PLoS ONE ◽  
2016 ◽  
Vol 11 (8) ◽  
pp. e0161116 ◽  
Author(s):  
Megan L. Lloyd ◽  
Nurul Hod ◽  
Jothsna Jayaraman ◽  
Elizabeth A. Marchant ◽  
Lukas Christen ◽  
...  
Keyword(s):  
Breast Milk ◽  
Treatment Option ◽  
Ultraviolet C ◽  
Milk Banking ◽  
New Treatment

scholarly journals Small cell carcinoma in ulcerative colitis - new treatment option: a case report

2010 ◽  
Vol 8 (1) ◽  
Author(s):  
Christoforos Kosmidis ◽  
Christoforos Efthimiadis ◽  
Georgios Anthimidis ◽  
Kalliopi Vasiliadou ◽  
Ioanna Tzeveleki ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Case Report ◽  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Treatment Option ◽  
Small Cell ◽  
New Treatment
Sign in / Sign up

Export Citation Format

Share Document